SCHEMBL5568271

SCHEMBL5568271

Cc1ccc2ncnc(Nc3cc(Cl)c(Cl)cc3Cl)c2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.65
MAPK1 P28482 2/20 0.65
KDM4E B2RXH2 2/20 0.65
MAPT P10636 2/20 0.62
LMNA P02545 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
NCOA1 Q15788 2/20 0.59
NCOA3 Q9Y6Q9 2/20 0.59
EGFR P00533 4/20 0.54
SRC P12931 2/20 0.54
RIPK2 O43353 1/20 0.54
NOD1 Q9Y239 1/20 0.54
RAF1 P04049 1/20 0.53
BRAF P15056 1/20 0.53
ERBB2 P04626 2/20 0.52
KDR P35968 3/20 0.51
ALDH1A1 P00352 2/20 0.51
HPGD P15428 2/20 0.51
RET P07949 2/20 0.51
KIF5B P33176 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5566231 0.87 SRC (0.65) HTTMAPK1KDM4EMAPTLMNA
SCHEMBL5569108 0.86 HTT (0.71) HTTMAPK1KDM4EMAPTLMNA
SCHEMBL30870402 0.86 HTT (0.71) HTTMAPK1KDM4EMAPTLMNA
SCHEMBL5564640 0.83 HTT (0.62) HTTMAPK1KDM4EMAPTLMNA
SCHEMBL5569927 0.82 KDM4E (0.74) HTTMAPK1KDM4EMAPTLMNA
SCHEMBL5564611 0.82 KDR (0.71) HTTMAPK1KDM4EMAPTLMNA
SCHEMBL5569117 0.82 HTT (0.61) HTTMAPK1KDM4EMAPTLMNA
SCHEMBL5569405 0.82 HTT (0.78) HTTMAPK1KDM4EMAPTLMNA
SCHEMBL26449347 0.81 EGFR (0.64) HTTMAPK1KDM4EMAPTLMNA
SCHEMBL14511293 0.80 NCOA1 (0.61) HTTMAPK1KDM4EMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US claimed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP claimed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO claimed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP disclosed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections IRF3, PML, TPMT HTT 2700/4885MAPK1 1019/4885KDM4E 1004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.